Purpose To identify predictors of oncologic outcomes after percutaneous radiofrequency ablation (RFA) of @entity14 (CLMs) and to describe and evaluate a modified @entity922 ( @entity922 ) adapted for ablation as a @entity1 stratification and prognostic tool. Materials and Methods This study consisted of a HIPAA-compliant institutional review board-approved retrospective review of data in 162 @entity1 with 233 CLMs treated with percutaneous RFA between December 2002 and December 2012. Contrast material-enhanced CT was used to assess technique effectiveness 4-8 weeks after RFA. @entity1 were followed up with contrast-enhanced CT every 2-4 months. @entity1349 ( @entity1349 ) and @entity5 progression-free survival (LTPFS) were calculated from the time of RFA by using the Kaplan-Meier method. Log-rank tests and Cox regression models were used for univariate and multivariate analysis to identify predictors of outcomes. Results Technique effectiveness was 94% (218 of 233). Median LTPFS was 26 months. At univariate analysis, predictors of shorter LTPFS were @entity5 size greater than 3 cm (P < .001), ablation margin size of 5 mm or less (P < .001), high modified @entity922 (P = .009), male sex (P = .03), and no history of prior hepatectomy (P = .04) or hepatic arterial infusion chemotherapy (P = .01). At multivariate analysis, only @entity5 size greater than 3 cm (P = .01) and margin size of 5 mm or less (P < .001) were independent predictors of shorter LTPFS. Median and 5-year @entity1349 were 36 months and 31%. At univariate analysis, predictors of @entity1349 were @entity5 size larger than 3 cm (P = .005), carcinoembryonic antigen level greater than 30 ng/mL (P = .003), high modified @entity922 (P = .02), and @entity6687 ( @entity6687 ) (P < .001). At multivariate analysis, @entity5 size greater than 3 cm (P = .006) and more than one site of @entity6687 (P < .001) were independent predictors of @entity1349 . Conclusion @entity5 size of less than 3 cm and ablation margins greater than 5 mm are essential for satisfactory @entity5 control. @entity5 size of more than 3 cm and the presence of more than one site of @entity6687 are associated with @entity1349 . (  ) RSNA, 2015.

Percutaneous Radiofrequency Ablation of XXXX : Factors Affecting Outcomes-A 10-year Experience at a Single Center.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'local tumor'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer liver metastases'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'shorter OS', 'Overall survival'] @entity6687 :: ('MESH:D001651', 'Disease') :: ['EHD', 'extrahepatic disease'] @entity922 :: ('MESH:D013568', 'Disease') :: ['clinical risk score', 'CRS']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal Cancer Liver Metastases']
